華脈科技(603042.SH):控股股東胥愛民持股比例降至22.98%
格隆匯7月20日丨華脈科技(603042.SH)公吿,經中國證券監督管理委員會相關文件的核準,公司向包含控股股東、實際控制人胥愛民在內的11名特定對象非公開發行人民幣普通股(A股)2458.984萬股。本次非公開發行中,胥愛民參與認購193.3593萬股。
2021年7月19日,公司在中國證券登記結算有限公司上海分公司完成了本次非公開發行新增股份登記事項。
據悉,本次非公開發行前,胥愛民持有公司3497.1428萬股股份,佔公司總股本的25.71%;本次非公開發行完成後,胥愛民持有公司3690.5021萬股股份,佔公司總股本的22.98%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.